Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results
2007 | 79 | 3 | 161-166

Article title

Pro-Atrial Natriuretic Peptide (proANP) A New Prognostic Marker in Clinical Outcome of Critically Ill Patients


Title variants

Languages of publication



The diagnosis of sepsis and the prediction of its outcome are important aims to tackle for this heterogeneous disease. There is a lack of biomarkers to aid in identification of risk groups, inclusion of patients in ongoing studies, and better differentiation of therapeutic strategies. Since the introduction of the prohormone procalcitonin (PCT), many studies have begun to focus on new prohormones.The aim of the study was to evaluate the prognostic value of pro-atrial natriuretic peptide (proANP) as a new marker of sepsis outcome.Material and methods. A cohort of 80 patients developing post-surgical sepsis was consecutively included into this study. Blood samples were obtained for analysis of proANP and determination the serum levels of sTNF-R1, TNF-α, IL-6, IL-8, IL-10, procalcitonin and neopterin. Cytokine levels were measured repeatedly until the patients discharge from the ICU.Results. 54/80 (67.5%) fulfilled the criteria for severe sepsis and 36/80 (45.0%) developed septic shock. Multiple organ failure occurred within 60/80 patients (75.0%); the overall mortality was 26/80 (32.5%). Concerning the diagnosis of sepsis, severe sepsis, or septic shock, there was no statistical difference in the proANP values. However, there was a statistical difference in the prediction of outcome in that 26 nonsurvivors had 803.5 (441.5/ 1095) pmol/L levels while the survivors level was 315.5 (187/ 594.5) pmol/L. In addition, there were no statistical significant differences between proANP and other cytokines.Conclusions. There was a significant correlation between proANP values and the outcome of critically ill patients. ProANP does not differentiate between clinical features like sepsis, severe sepsis or septic shock.








Physical description


1 - 3 - 2007
24 - 9 - 2007


  • Department of General Surgery, Klinikum Konstanz Teaching Hospital of the University, Freiburg
  • Surgical University Clinic of Würzburg, Germany


  • Dinarello CA: Proinflammatory and Antiinflammatory Cytokines as mediators in the pathogenesis of septic shock. Chest 1997; 112 (suppl 6): 321s-329s.[Crossref]
  • Mira JP, Cariou A, Grall F et al.: Association of TNF2, a TNF-α Promotor Polymorphism, with septic Shock Susceptibility and Mortality. JAMA 1999; 282/6: 561-68.
  • Spies T, Morton CC, Nedospasov SA et al.: Genes for tumor necrosis factors a and b are linked to the human major histocompatibility complex. Proc Natl Acad Sci USA 1986; 83: 8699.
  • Reith HB, Mittelkötter U, Debus ES et al.: Procalcitonin in early detection of postoperative Complications. Dig Surg 1998; 15: 260-65.[PubMed][Crossref]
  • Vesely DL: Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life 2002; 53: 153-59.
  • Witthaut R: Science review: natriuretic peptides in criticall illness. Crit Care Med 2004; 8: 342-49.
  • Morgenthaler NG, Struck J, Thomas B et al.: Immunoluminometric assay fort he midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004; 50: 234-36.[Crossref]
  • Morgenthaler NG, Struck J, Christ-Crain M et al.: Pro-atrial natriuretic peptide is a prognostic marker similar to APACHE II score: an observational study. Crit Care 2005; 9: R37-45.[Crossref]
  • Brueckmann M, Huhle G, Lang S et al.: Prognostic vakue of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2006; 113: e25.
  • Schlüter B, Konig B, Bergmann U et al.: Interleukin 6 - a potential mediator of lethal sepsis after major thermal trauma: Evidence for increased IL-6 production by peripheral blood mononuclear cells. J Trauma 1991; 31: 1663-70.[Crossref][PubMed]
  • Borden EC, Chin P: Interleukin 6: a cytokine with potential diagnostic and therapeutic roles. J Lab Clin Med 1994; 123: 824-29.
  • Abul H, Abul A, Khan I et al.: Levels of IL-8 and myeloperoxidase in the lungs of pneumonia patients. Mol Cell Biochem 2001; 217: 107-12.
  • Oberholzer A, Oberholzer C, Moldawer LL: Interleukin 10: A complex role on the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002; 30: S58-S63.[Crossref]
  • Reith HB, Mittelkötter U, Maseizik T et al.: Peritonitis- Monitoring mit Procalcitonin und Diagnostik von Immunfunktionsstörungen durch HLA-DR-Expression auf Monzyten. Chir Gastroenterol 1999; 15/S1: 8-14.
  • Huber C, Batchelor JR, Fuchs D et al.: Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160: 310-16.
  • Goris RJ, te-Boekhorst TP, Nuytinck JK et al.: Multiple-Organ Failure: Generalized autodestructive inflammation? Arch Surg 1985; 120: 1109-15.
  • Knaus of WA, Draper EA, Wagner DP et al.: APACHE II. A severity of disease classification system. Critical Care Medicine 1985; 10: 818-29.[Crossref]
  • Bone RC, Balk RA, Cerra FB et al.: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Comittee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
  • Rauchschwalbe SK, Maseizik T, Mittelkötter U et al.: Effect of the LT-α (+250G/A) polymorphism on markers of inflammation and clinical outcome in critically ill patients. J Trauma 2004; 56: 815-22.
  • Ruskoaho H: Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003; 24: 341-56.[PubMed][Crossref]
  • Abraham E, Anzueto A, Guttierez G et al.: Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. NORASEPT II study group. Lancet 1998; 351: 929-33.
  • Spielmann S, Kerner T, Ahlers O et al.: Early detection of increased tumor necrosis factor alpha (TNFα) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. Acta Anaesthesiol Scand 2001; 45: 364-70.
  • Gogos AC, Drosou E, Bassaris HP et al.: Proversus Anti-inflammatory Cytokine Profile in Patients with Severe Sepsis: A Marker for Prognosis and Future Therapeutic Options. J Infect Dis 2000; 181: 176-80.
  • Dehoux MS, Boutten A, Ostinelli J et al.: Compartimentation of cytokine production within the human lung unilateral pneumonia. Am J Respir Crit Care Med 1994; 150: 710-16.
  • Bonten MJM, Froon AHM, Gaillard CA et al.: The systemic inflammatory response in development of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156: 1105-13.
  • Strohmaier W, Redl H, Schlag G et al.: D-Erythro-neopterin plasma level in intensive care patients with or without septic complications. Crit Care Med 1987; 15: 581-87.
  • Dellinger RP, Carlet JM, Masur H et al.: Surviving sepsis campaign guidelines for management of severe Sepsis and septic shock. Crit Care Med 2004; 32: 858-73.[Crossref][PubMed]
  • Christ-Crain M, Jaccard-Stolz D, Bingisser R et al.: Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infection: cluster-randomized, single-blinded intervention trial. Lancet 2004; 363: 600-07.

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.